Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
Public ClinicalTrials.gov record NCT00088283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to CRVO
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This investigational drug may slow the growth of abnormal blood vessels in the eye and may reduce tissue swelling in the eye. The purpose of this study is to compare the safety and efficacy of a Macugen™ injection to a "pretend" injection. In addition, the purpose of this study is to measure the action of the study drug in the body over a period of time and to check for the presence of the study drug in your blood (called pharmacokinetics or PK). This study will involve approximately 90 people. People who decide to participate will have an equal chance (1 in 3) to receive one of three study injections, two of which are Macugen™ and one of which is a "pretend" injection.
Study identification
- NCT ID
- NCT00088283
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2004 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jan 19, 2007
Started 2004
United States locations
- U.S. sites
- 35
- U.S. states
- 21
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retina Centers, P.C., Northwest Location | Tucson | Arizona | 85704 | — |
| Retina Associates, SW | Tucson | Arizona | 85710 | — |
| Jules Stein Institute | Los Angeles | California | 90095 | — |
| Orange County Retina Associates | Santa Ana | California | 92705 | — |
| New England Retina Associates | Hamden | Connecticut | 06518 | — |
| Retina Group of Florida | Fort Lauderdale | Florida | 33334 | — |
| Bascom Palmer Eye Institute | Miami | Florida | 33136 | — |
| The University of Chicago | Chicago | Illinois | 60637 | — |
| Macula-Retina-Vitreous Service | Indianapolis | Indiana | 46280 | — |
| Vitreo-Retinal Consultants & Surgeons, P.A. | Wichita | Kansas | 67214 | — |
| Retina Associates | New Orleans | Louisiana | 70155 | — |
| Retina Group of Washington | Chevy Chase | Maryland | 20815 | — |
| Cumberland Valley Retina Center | Hagerstown | Maryland | 21740 | — |
| New England Eye Center | Boston | Massachusetts | 02111 | — |
| Massachusetts Eye & Ear Infirmary | Boston | Massachusetts | 02114 | — |
| Lahey Clinic, The Eye Institute | Peabody | Massachusetts | 01960 | — |
| Kresge Eye Institute | Detroit | Michigan | 48201 | — |
| Associated Retinal Consultants | Royal Oak | Michigan | 48073 | — |
| Eye Foundation of Kansas City | Kansas City | Missouri | 64108 | — |
| Charlotte Eye, Ear, Nose and Throat Associates, P.A. | Charlotte | North Carolina | 28210 | — |
| Duke University Eye Center | Durham | North Carolina | 27710 | — |
| The Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Retina Associates of Cleveland Inc. | Lakewood | Ohio | 44107 | — |
| Dean A. McGee Eye Institute | Oklahoma City | Oklahoma | 73104 | — |
| Casey Eye Institute | Portland | Oregon | 97239 | — |
| Wills Eye Institute Retina Research | Philadelphia | Pennsylvania | 19107 | — |
| Palmetto Retina Center | Columbia | South Carolina | 29204 | — |
| Southeastern Retina Associates | Knoxville | Tennessee | 37909 | — |
| Retina Research Institute of Texas, LLC | Abilene | Texas | 79606 | — |
| Austin Retina Associates | Austin | Texas | 78705 | — |
| Texas Retina Associates | Dallas | Texas | 75231 | — |
| VitreoRetinal Consultants | Houston | Texas | 77030 | — |
| Valley Retina Associates, P.A. | McAllen | Texas | 78503 | — |
| University of Wisconsin | Madison | Wisconsin | 53705 | — |
| The Eye Institute | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00088283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2007 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00088283 live on ClinicalTrials.gov.